Achmea Investment Management B.V. Grows Position in Abbott Laboratories (NYSE:ABT)

Achmea Investment Management B.V. raised its position in Abbott Laboratories (NYSE:ABT) by 1.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 115,277 shares of the healthcare product maker’s stock after buying an additional 1,281 shares during the quarter. Achmea Investment Management B.V.’s holdings in Abbott Laboratories were worth $11,979,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. lifted its position in Abbott Laboratories by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 156,467,081 shares of the healthcare product maker’s stock worth $17,222,332,000 after acquiring an additional 701,740 shares during the period. Sanibel Captiva Trust Company Inc. purchased a new position in Abbott Laboratories in the 4th quarter valued at $16,764,000. Garde Capital Inc. increased its stake in Abbott Laboratories by 16.4% in the 4th quarter. Garde Capital Inc. now owns 1,858 shares of the healthcare product maker’s stock valued at $205,000 after buying an additional 262 shares during the period. Haverford Trust Co lifted its stake in shares of Abbott Laboratories by 0.7% in the 4th quarter. Haverford Trust Co now owns 93,879 shares of the healthcare product maker’s stock worth $10,333,000 after acquiring an additional 664 shares during the period. Finally, Sectoral Asset Management Inc. boosted its holdings in shares of Abbott Laboratories by 31.4% in the fourth quarter. Sectoral Asset Management Inc. now owns 68,998 shares of the healthcare product maker’s stock valued at $7,595,000 after acquiring an additional 16,500 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

ABT stock opened at $116.84 on Friday. The stock’s 50 day moving average price is $108.99 and its 200 day moving average price is $108.74. The firm has a market cap of $203.26 billion, a P/E ratio of 36.40, a PEG ratio of 2.83 and a beta of 0.72. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.68. Abbott Laboratories has a 1 year low of $89.67 and a 1 year high of $121.64.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 18th. The healthcare product maker reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.04. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The business had revenue of $10.38 billion for the quarter, compared to analyst estimates of $10.37 billion. During the same quarter last year, the company earned $1.08 earnings per share. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. On average, sell-side analysts expect that Abbott Laboratories will post 4.66 earnings per share for the current fiscal year.

Analyst Ratings Changes

ABT has been the subject of a number of recent analyst reports. Evercore ISI reduced their price objective on shares of Abbott Laboratories from $125.00 to $120.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Barclays lifted their price target on Abbott Laboratories from $140.00 to $143.00 and gave the company an “overweight” rating in a research note on Monday, July 29th. Edward Jones cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday, July 30th. Citigroup upped their price target on shares of Abbott Laboratories from $119.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Abbott Laboratories in a research note on Tuesday, June 4th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $121.80.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.